Pelthos Therapeutics Valuation Multiples
Pelthos Therapeutics is valued at $37M as of November 2026, a 1.5x revenue multiple. In the last 12 months, Pelthos Therapeutics revenue was $56M and Pelthos Therapeutics EBITDA was ($32M).
Pelthos Therapeutics Overview
About Pelthos Therapeutics
Pelthos Therapeutics Inc is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
Founded
2021
HQ
Employees
11
Website
Financials (LTM)
EV
$86M
Valuation Multiples
Start free trial
Pelthos Therapeutics Financials
Pelthos Therapeutics reported last 12-month revenue of $56M and negative EBITDA of ($32M).
In the same LTM period, Pelthos Therapeutics generated $44M in gross profit, ($32M) in EBITDA losses, and had net loss of ($62M).
Revenue (LTM)
Pelthos Therapeutics P&L
In the most recent fiscal year, Pelthos Therapeutics reported revenue of $17M and EBITDA of ($45M).
Pelthos Therapeutics is unprofitable as of last fiscal year, with gross margin of 44%, EBITDA margin of (270%), and net margin of (258%).
Financial data powered by Morningstar, Inc.
Pelthos Therapeutics Stock Performance
Pelthos Therapeutics has current market cap of $37M, and enterprise value of $86M.
Market Cap Evolution
Pelthos Therapeutics' stock price is $9.36.
Pelthos Therapeutics share price decreased by 0.4% in the last 30 days.
Pelthos Therapeutics has an EPS (earnings per share) of $-11.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $86M | $37M | 0.0% | -0.4% | - | - | $-11.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPelthos Therapeutics Valuation Multiples
Pelthos Therapeutics trades at 1.5x EV/Revenue multiple, and (2.7x) EV/EBITDA.
EV / Revenue (LTM)
Pelthos Therapeutics Financial Valuation Multiples
As of November 8, 2026, Pelthos Therapeutics has market cap of $37M and EV of $86M.
Pelthos Therapeutics has a P/E ratio of (0.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pelthos Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pelthos Therapeutics Margins & Growth Rates
Pelthos Therapeutics grew revenue by 270% but EBITDA decreased by 26% in the last fiscal year.
In the most recent fiscal year, Pelthos Therapeutics reported gross margin of 44%, EBITDA margin of (270%), and net margin of (258%).
Pelthos Therapeutics Margins
Pelthos Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Pelthos Therapeutics Operational KPIs
Pelthos Therapeutics' revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $4.5M for the same period.
Pelthos Therapeutics' Rule of 40 is 216% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pelthos Therapeutics' Rule of X is 621% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Pelthos Therapeutics Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Pelthos Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Pelthos Therapeutics
Pelthos Therapeutics has acquired 1 company to date.
Last acquisition by Pelthos Therapeutics was on October 30th 2026. Pelthos Therapeutics acquired Castle Creek Biosciences for undisclosed valuation.
Latest Acquisitions by Pelthos Therapeutics
| Description | Castle Creek Biosciences is a Pennsylvania-headquartered developer of gene-corrected cell therapies for dystrophic epidermolysis bullosa and recessive DEB. Its FCX-007 product uses CRISPR editing on patient fibroblasts for intradermal injections. Founded in 2015 and acquired by KRUUSE in 2022, the company conducts Phase 1/2 trials at sites in the US and Europe. |
| HQ Country | |
| HQ City | Philadelphia, PA |
| Deal Date | 30 Oct 2026 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Pelthos Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pelthos Therapeutics
| When was Pelthos Therapeutics founded? | Pelthos Therapeutics was founded in 2021. |
| Where is Pelthos Therapeutics headquartered? | Pelthos Therapeutics is headquartered in United States. |
| How many employees does Pelthos Therapeutics have? | As of today, Pelthos Therapeutics has over 11 employees. |
| Is Pelthos Therapeutics publicly listed? | Yes, Pelthos Therapeutics is a public company listed on NYSE American. |
| What is the stock symbol of Pelthos Therapeutics? | Pelthos Therapeutics trades under PTHS ticker. |
| When did Pelthos Therapeutics go public? | Pelthos Therapeutics went public in 2024. |
| Who are competitors of Pelthos Therapeutics? | Pelthos Therapeutics main competitors include |
| What is the current market cap of Pelthos Therapeutics? | Pelthos Therapeutics' current market cap is $37M. |
| What is the current revenue of Pelthos Therapeutics? | Pelthos Therapeutics' last 12 months revenue is $56M. |
| What is the current revenue growth of Pelthos Therapeutics? | Pelthos Therapeutics revenue growth (NTM/LTM) is 83%. |
| What is the current EV/Revenue multiple of Pelthos Therapeutics? | Current revenue multiple of Pelthos Therapeutics is 1.5x. |
| Is Pelthos Therapeutics profitable? | No, Pelthos Therapeutics is not profitable. |
| What is the current EBITDA of Pelthos Therapeutics? | Pelthos Therapeutics has negative EBITDA and is not profitable. |
| What is Pelthos Therapeutics' EBITDA margin? | Pelthos Therapeutics' last 12 months EBITDA margin is (57%). |
| What is the current EV/EBITDA multiple of Pelthos Therapeutics? | Current EBITDA multiple of Pelthos Therapeutics is (2.7x). |
| How many companies Pelthos Therapeutics has acquired to date? | As of November 2026, Pelthos Therapeutics has acquired 1 company. |
| What was the largest acquisition by Pelthos Therapeutics? | None of the M&A deals Pelthos Therapeutics has completed have disclosed valuations. |
| What companies Pelthos Therapeutics acquired? | Pelthos Therapeutics acquired Castle Creek Biosciences. |
| In how many companies Pelthos Therapeutics has invested to date? | Pelthos Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.